Zydus Lifesciences Acquires Mylab – An Unprecedented Collaboration
In a significant move towards transforming the healthcare landscape, Zydus Lifesciences Limited has acquired a 6.5% stake in Mylab Discovery Solutions. Zydus Lifesciences successfully completed a strategic acquisition through its fully owned subsidiary, Zydus Animal Health & Investments Limited (ZAHIL).
The stake was purchased from Rising Sun Holdings, an investment company owned by the well-known entrepreneur Adar Poonawalla. The primary objective behind this acquisition is to combine the therapeutic expertise in human formulations of Zydus Lifesciences with the diagnostic capabilities of Mylab. Both companies share a collective vision of revolutionizing healthcare through innovation, advanced diagnostics, and effective treatments.
Mylab Discovery Solutions, known for its research and development capabilities in diagnostics, brings valuable expertise to the partnership. With Zydus Lifesciences’ established presence in therapeutics and extensive last-mile access, the collaboration aims to bring decentralized healthcare solutions to the masses.
This approach has the potential to empower individuals, healthcare providers, and communities by providing them with timely and accurate diagnostics, as well as localized healthcare services. Hasmukh Rawal, the Managing Director of Mylab, expressed his excitement about the partnership, stating, “Combining Zydus’ research and development capabilities in therapeutics with Mylab’s expertise in diagnostics, along
with Zydus’ last-mile access, has the potential to bring decentralized healthcare solutions to the masses.By focusing on decentralized healthcare, we can provide individuals, healthcare providers, and communities with timely and accurate diagnostics, effective treatments, and localized healthcare services.” Sujit Jain, Director of Strategy at Mylab Discovery Solutions, highlighted the groundbreaking nature of the partnership, saying, “This is the first time in India that a pharmaceutical company, a diagnostic company, and a vaccine manufacturer are joining forces. I am confident that this partnership will revolutionize the way diseases are diagnosed, treated, and prevented.”
The collaboration between Zydus Lifesciences and Mylab creates synergies that hold great promise for advancements in precision medicine, personalized treatments, and preventive care. By combining their expertise, the two companies aim to foster innovation, encourage cross-disciplinary collaboration, and pave the way for new discoveries and therapies that can have a positive impact on the healthcare industry.
It’s important to note that the completion of the transaction is subject to customary closing conditions. However, both companies are optimistic about the potential of this partnership and eagerly anticipate the positive changes it can bring to healthcare delivery.
This acquisition marks a significant milestone in the healthcare sector, demonstrating the power of collaboration between pharmaceutical companies and diagnostic experts. With the collective vision of Zydus Lifesciences and Mylab Discovery Solutions, the future holds great promise for advancements in healthcare, as they work together to transform the way diseases are diagnosed, treated, and prevented.
